Lilly's Oral GLP-1 Orforglipron Demonstrates Efficacy In Type 2 Diabetes Treatment In Phase 3 Trial
22/6 19:29
(RTTNews) - Eli Lilly And Co.'s (LLY) investigational oral GLP-1 receptor agonist, orforglipron, demonstrated compelling efficacy and a safety profile aligned with that of injectable GLP-1 therapies, according to full Phase 3 results published in The New England Journal of Medici...